Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

1P9S

Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of anti-SARS Drugs

Summary for 1P9S
Entry DOI10.2210/pdb1p9s/pdb
Related1LVO 1P9T 1P9U
DescriptorReplicase polyprotein 1ab, 1,4-DIETHYLENE DIOXIDE (3 entities in total)
Functional Keywordssars-cov, hcov, coronavirus, tgev, hydrolase
Biological sourceHuman coronavirus
Total number of polymer chains2
Total formula weight66798.68
Authors
Anand, K.,Ziebuhr, J.,Wadhwani, P.,Mesters, J.R.,Hilgenfeld, R. (deposition date: 2003-05-12, release date: 2003-05-20, Last modification date: 2024-10-30)
Primary citationAnand, K.,Ziebuhr, J.,Wadhwani, P.,Mesters, J.R.,Hilgenfeld, R.
Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of anti-SARS Drugs
Science, 300:1763-1767, 2003
Cited by
PubMed Abstract: A novel coronavirus has been identified as the causative agent of severe acute respiratory syndrome (SARS). The viral main proteinase (Mpro, also called 3CLpro), which controls the activities of the coronavirus replication complex, is an attractive target for therapy. We determined crystal structures for human coronavirus (strain 229E) Mpro and for an inhibitor complex of porcine coronavirus [transmissible gastroenteritis virus (TGEV)] Mpro, and we constructed a homology model for SARS coronavirus (SARS-CoV) Mpro. The structures reveal a remarkable degree of conservation of the substrate-binding sites, which is further supported by recombinant SARS-CoV Mpro-mediated cleavage of a TGEV Mpro substrate. Molecular modeling suggests that available rhinovirus 3Cpro inhibitors may be modified to make them useful for treating SARS.
PubMed: 12746549
DOI: 10.1126/science.1085658
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.54 Å)
Structure validation

246704

PDB entries from 2025-12-24

PDB statisticsPDBj update infoContact PDBjnumon